Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
Mendez LC, Ravi A, Chung H, Tseng CL, Wronski M, Paudel M, McGuffin M, Cheung P, Loblaw A, Morton G. Mendez LC, et al. Among authors: tseng cl. Brachytherapy. 2018 Mar-Apr;17(2):291-297. doi: 10.1016/j.brachy.2017.10.001. Epub 2017 Nov 11. Brachytherapy. 2018. PMID: 29137956
Impact of Magnetic Resonance Imaging on Gross Tumor Volume Delineation in Non-spine Bony Metastasis Treated With Stereotactic Body Radiation Therapy.
Raman S, Chin L, Erler D, Atenafu EG, Cheung P, Chu W, Chung H, Loblaw A, Poon I, Rubenstein J, Soliman H, Sahgal A, Tseng CL. Raman S, et al. Among authors: tseng cl. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):735-743.e1. doi: 10.1016/j.ijrobp.2018.03.010. Epub 2018 Mar 17. Int J Radiat Oncol Biol Phys. 2018. PMID: 29748100
Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer.
Martell K, Mendez LC, Chung H, Tseng CL, Zhang L, Alayed Y, Liu S, Vesprini D, Chu W, Paudel M, Cheung P, Szumacher E, Ravi A, Loblaw A, Morton G. Martell K, et al. Among authors: tseng cl. Radiother Oncol. 2019 Jun;135:170-177. doi: 10.1016/j.radonc.2019.03.007. Epub 2019 Mar 27. Radiother Oncol. 2019. PMID: 31015164
Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy.
Lee SL, Ravi A, Morton G, Loblaw A, Tseng CL, Haider M, Murgic J, Nicolae A, Semple M, Chung HT. Lee SL, et al. Among authors: tseng cl. Brachytherapy. 2019 Sep-Oct;18(5):567-573. doi: 10.1016/j.brachy.2019.04.006. Epub 2019 May 22. Brachytherapy. 2019. PMID: 31126856
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.
Thompson R, Cheung P, Chu W, Myrehaug S, Poon I, Sahgal A, Soliman H, Tseng CL, Wong S, Ung Y, Beatriz Kinupe Abrahão A, Erler D, Zhang L, Ko YJ, Chung HT. Thompson R, et al. Among authors: tseng cl. Radiother Oncol. 2020 Jan;142:236-245. doi: 10.1016/j.radonc.2019.08.018. Epub 2019 Sep 19. Radiother Oncol. 2020. PMID: 31543287
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Loblaw A. Morton G, et al. Among authors: tseng cl. Radiother Oncol. 2020 May;146:90-96. doi: 10.1016/j.radonc.2020.02.009. Epub 2020 Mar 5. Radiother Oncol. 2020. PMID: 32146259 Clinical Trial.
315 results